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Abstract
The genetic basis of sporadic colorectal cancer (CRC) is not well explained by known risk 
polymorphisms. Here we perform a meta-analysis of two genome-wide association studies in 
2,627 cases and 3,797 controls of Japanese ancestry and 1,894 cases and 4,703 controls of African 
ancestry, to identify genetic variants that contribute to CRC susceptibility. We replicate genome-
wide statistically significant associations (P < 5×10−8) in 16,823 cases and 18,211 controls of 
European ancestry. This study reveals a new pan-ethnic CRC risk locus at 10q25 (rs12241008, 
intronic to VTI1A; P=1.4×10−9), providing additional insight into the etiology of CRC and 
highlighting the value of association mapping in diverse populations.
Introduction
CRC is the third most common cancer and the second leading cause of cancer deaths in the 
U.S. Genetics is known to play an important role in CRC susceptibility1. However, genome-
wide association studies (GWAS), mostly conducted in European-descent populations, have 
only identified 30 common risk variants (22 independent loci) for CRC, markedly fewer 
than for prostate or breast cancer.
To discover additional risk loci for this cancer, we combine, via a meta-analysis, two GWAS 
of CRC in populations of Japanese and African American ancestry. The top associations for 
SNPs in VTI1A are replicated in European-descent populations.
Results
In the first GWAS, Japanese samples (n = 6,424) were identified from the Multiethnic 
Cohort study (MEC), the Colorectal Cancer Family Registry (CCFR), the Japan Public 
Health Center cohort study (JPHC) and three case-control studies in Hawaii (CR2&3) and in 
Fukuoka and Nagano, Japan (Supplementary Table 1). Blood leukocyte DNA samples were 
genotyped on the Illumina 1M-Duo or the Illumina 660W-Quad arrays yielding, after quality 
control (QC) procedures, data for 323,852 SNPs available for all Japanese samples (see 
Methods and Supplementary Methods). Un-typed markers or markers with partly missing 
values were imputed with BEAGLE2 using East Asians from the 1000 Genomes Project 
(phase 1, release 3) as the reference panel. The second GWAS of African American samples 
(n = 6,597) (Supplementary Table 2) were identified from the MEC, CCFR, the Southern 
Community Cohort Study (SCCS), the MD Anderson Cancer Center, the University of 
North Carolina CanCORS study (UNCCanCORS) and Rectal Cancer Study (UNC-Rectal), 
and from the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) Trial. 
African American samples were genotyped using the Illumina 1M-Duo bead arrays (except 
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170 PLCO subjects on Illumina Omni 2.5M). Imputation was performed with BEAGLE 
using Europeans and Africans from the 1000 Genomes Project (phase 1, release 3) as 
reference panels. Over 4.2 million genotyped or imputed autosomal markers were available 
for both studies.
In both GWAS, cases and controls were well matched with regard to genetic ancestry based 
on principal component analyses (Methods and Supplementary Figures 1&2). We used 
logistic regression within each ethnic group to test for SNP dosage association with CRC 
risk, adjusting for age at blood draw, sex and the first 4 principal components (PCs). The 
genomic control3 inflation factor (λ) was 1.04 for each individual study, indicating little 
effect of population stratification after controlling for global ancestries (Supplementary Fig. 
3).
After combining the two GWAS, we observed three SNPs in the VTI1A gene on 
chromosome 10q25 to be statistically significant at the genome-wide significance level (P < 
5×10−8; Fig. 1; Table 1). The strongest association was for rs12241008 (114,280,702 bp) 
[odds ratio (OR) = 1.19, 95% CI 1.12-1.26, P = 2.9×10−8, allele frequency 0.19 and 0.25 in 
African Americans and Japanese, respectively] with highly consistent associations in both 
populations (I2 = 0). The other two SNPs, rs7894915 (114,277,039 bp, P = 4.8×10−8) and 
rs10082356 (114,278,181 bp, P = 4.9×10−8), are in high LD with rs12241008 (r2 from 0.80 
to 1.0 in East Asians, Africans and Europeans) with risk estimates almost identical to those 
for rs12241008 (Supplementary Tables 3 & 4). This locus has not previously been reported 
to be associated with CRC.
We subsequently replicated these associations in two large colorectal cancer consortia of 
European-descent populations (allele frequency 0.09): Colorectal Transdisciplinary Study 
(CORECT) with 7,561 cases and 6,328 controls from 8 participating studies (combined OR 
= 1.09, P = 0.036, Table 1) and Genetics and Epidemiology of Colorectal Cancer 
Consortium (GECCO) with 9,262 cases and 11,883 controls from 18 participating studies 
(combined OR = 1.09, P = 0.018, Table 1). The combined P-value for rs12241008 in the 
Japanese, African Americans and Europeans was 1.4×10−9 (OR = 1.13, 95% CI 1.09-1.18). 
A meta-analysis using individual study-level statistics yielded similar results (P = 1.5×10−9). 
Although risk estimates were consistent across individual studies (I2 = 8%, Phet = 0.35, 
d.f.=27) (see forest plot in Supplementary Fig. 4), there was some evidence for 
heterogeneity in effects across ethnic groups (I2 = 53%, Phet=0.12, d.f.=2). This possible 
heterogeneity in effects, along with the low allele frequencies observed in European-descent 
populations (and therefore low power), could partially explain why previous GWAS in 
Europeans failed to identify this locus and thus, emphasizes the importance of conducting 
GWAS in ethnically diverse populations.
Similar results were observed for rs7894915 and rs10082356 when the data were combined 
with the European-descent GWAS (P = 1.6×10−9 and 1.5×10−9, respectively). Nine other 
SNPs in this region (located within 12kb in the same LD block as rs12241008 in East 
Asians, Africans and Europeans, Supplementary Fig. 5) also had P-values < 5×10−8 when 
all data were combined (Supplementary Tables 3 & 4). However, the strongest association 
signal was still with rs12241008 (Supplementary Fig. 5) and none of the other nearby SNPs 
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within 200kb represented an independent signal after conditioning on rs12241008 in the 
African American and Japanese GWAS. Results for these 12 SNPs were similar (change in 
OR <1.2%) with or without adjustment for local ancestry estimates among African 
Americans (Methods).
There was no important heterogeneity in ORs in the Japanese or the African American data 
by anatomical site (colon vs. rectal cancer) (P-values > 0.74), by stage (regional/distant vs. 
local/in situ) (P-values > 0.6), by age of diagnosis (P-values > 0.7), or by sex (P = 0.04 in 
African Americans and 0.80 in Japanese) for the most significant marker rs12241008 
(stratified analysis results are in Supplementary Table 5).
No association reached the genome-wide significance threshold (5×10−8) in the Japanese 
GWAS when analyzed separately. One SNP on chromosome 7, rs79453636, passed this 
threshold (P = 2.9×10−8) in the African American study (Supplementary Fig. 3). However, 
this association was not replicated (Supplementary Table 6) in the Japanese or in the 
combined European-descent data (P-values > 0.15).
Out of 30 known CRC susceptibility SNPs, 27 were available for analysis in the Japanese 
study and 23 (85%) effects were in the same direction as in original GWAS reports 
(Supplementary Table 7). Replication and fine-mapping of the known risk loci in the 
African American study was summarized previously4. Twelve out of the 27 associations 
were replicated in the meta-analysis of the Japanese and African American data (P < 0.05) 
and 23 risk estimates were directionally consistent with those originally reported 
(Supplementary Table 7). Considerable heterogeneity in disease risk between the two ethnic 
groups (I2 > 50%) was observed for 6 SNPs (Supplementary Table 7).
The three genetic variants with the strongest association with CRC, rs12241008, rs7894915 
and rs10082356, are located in intron 3 of the VTI1A gene which encodes vesicle transport 
through interaction with t-SNAREs 1A. VTI1A is involved in regulating insulin-stimulated 
trafficking of secretory vesicles enriched with both GLUT4 (glucose transporter) and 
Acrp30 in adipocytes5; it also plays key roles in neuronal development 6 and in selectively 
maintaining spontaneous neurotransmitter release7. A recent GWAS study in never-smoking 
Asian women has identified rs7086803 in intron 7 of VTI1A as a lung cancer susceptibility 
variant (218kb from and not in LD with rs12241008)8. Interestingly, a gene fusion product, 
VTI1A-TCF7L2, was identified in colorectal tumors and shown to promote anchorage-
independent growth of cultured tumor cells9. The fusion occurs between VTI1A exon 3 
(chr10:114,220,869) and TCF7L2 exon 4 (chr10:114,760,545) and results in the deletion of 
both the intron 3 CRC and intron 7 lung cancer risk variants. No coding variant is in LD 
with the top three SNPs. Among the three VTI1A SNPs associated with CRC in this study, 
rs7894915 and rs10082356 lie in predicted transcriptional regulatory regions suggesting 
enhancer and promoter regulatory activities across multiple cell lines (Supplementary Table 
8)10. We explored regulatory effects of the SNPs correlated with rs12241008 in a cis-
expression quantitative trait loci (cis-eQTL) analysis in 40 paired colon adjacent-normal and 
tumor tissue samples from European descent patients11. Among the SNPs in high LD (r2 > 
0.8) with rs12241008 in East Asians, the intronic SNP rs7081965 (alleles: A/T), affected 
VTI1A expression (P = 0.003) in colon tumor tissue. Rs7081965 is also in considerable LD 
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with rs12241008 in Africans (r2 = 0.21, |D’| = 0.88) and in Europeans (r2 = 0.24, |D’| =1) in 
the 1000 Genomes data. Although the association of rs7081965 with CRC was not 
statistically significant in this study (OR = 1.09 for allele T, P = 8.2×10−6 from three ethnic 
groups combined), these results provide an interesting lead for future functional 
investigations.
In summary, this trans-ethnic GWAS identified a new CRC susceptibility locus at 10q25 
with directionally consistent associations across three ethnic/racial populations, providing 
additional insight into the genetic architecture of CRC. Further work is needed to dissect this 
genetic signal and to conduct functional studies to uncover the mechanisms underlying this 
association.
Methods
Japanese subjects and quality control on genotypes
Details on study design and basic characteristics for each study are provided in 
Supplementary Methods. Briefly, 1,703 MEC Japanese American subjects were genotyped 
by the Broad Genotyping Center on the Illumina 1M-Duo Array and 1,602 (803 cases, 799 
controls) passed their initial QC filters. To maximize sample size, initially “failed” samples 
on five plates were re-clustered with a customized genotype calling algorithm – this step 
recovered 42 additional MEC subjects (23 cases, 19 controls), although not all SNPs on the 
array were preserved. To increase statistical power and to provide a larger control pool, 
1,033 prostate cancer-free men genotyped and 808 breast cancer-free women genotyped on 
the Illumina 660W Quad platform were drawn from the MEC prostate cancer (MEC-
PrCa) 13 and breast cancer (MEC-BrCa) 14 studies, respectively.
Japanese from the following studies were all genotyped on the Illumina 1M-Duo array by 
the University of Southern California (USC) Epigenome Center: 697 from CCFR (384 
cases, 313 controls), 155 cases from CR2&3, 1,463 from Fukuoka, Japan (685 cases, 778 
controls), 212 from Nagano, Japan (106 cases, 106 controls) and 1,332 from JPHC (670 
cases, 662 controls). In general, all genotyped samples were examined and excluded 
according to the following: 1) call rates < 90%, 95% or 97% depending on the batches, 2) 
missing on basic covariates (age, sex or disease status), 3) gender mismatch, i.e. the reported 
sex is different from that estimated based on X chromosome inbreeding coefficient F, 
calculated by PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/), 4) ethnicity outliers, i.e. 
subjects fell out of the Japanese cluster (by visual inspection) on principal components (PCs) 
plots, where PCs were derived for study subjects as well as unrelated HapMap CEU, YRI 
and JPT samples with our own R program (The Comprehensive R Archive Network http://
www.r-project.org/), based on about 20k SNPs with inter-marker distance > 100kb, and 5) 
close (≥ 2nd degree) relatives, where relationships were derived from estimated probabilities 
of sharing 0, 1, or 2 allele based on genomic data (calculated by PLINK) and relatives were 
removed in the following order: subjects with most relatives, controls, and subjects with 
lower call rates. All cases were verified by histological records to have invasive carcinoma 
of the colon or rectum. More details on genotype QC can be found in Supplementary 
Methods. After QC, the following subjects were retained in analysis: 3,094 from the MEC 
(797 cases, 2,297 controls), 285 from CCFR (276 cases and 9 controls), 134 cases from 
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CR2&3, 1,411 from Fukuoka, Japan (662 cases, 749 controls), 207 from Nagano, Japan 
(105 cases, 102 controls) and 1,293 from the JPHC (653 cases, 640 controls).
African American subjects and QC on genotypes
Sample collection and genotyping QC have been described in details elsewhere 4 and in 
Supplementary Methods. We genotyped 7,168 African Americans samples from six studies/
centers: the MEC (442 cases, 4,620 controls), CCFR (999 cases, 290 controls), SCCS (164 
cases, 160 controls), the MD Anderson Cancer Center (189 cases), UNC-CanCORS (84 AA 
cases) and UNC-Rectal (112 cases, 108 controls) on the Illumina 1M-duo platform. QC 
procedures for all subjects were similar to the criteria described for the Japanese study 
subjects. Included in analysis were 6,427 subjects (4,609 controls, 1,818 cases) on 1,049,327 
markers. We also included 170 PLCO samples (76 cases, 94 controls) that were previously 
genotyped on the Illumina Omni 2.5M array and pre-filtered by the NCI genotyping center 
for analysis (527,383 markers that overlapped with other studies). Overall, 6,597 subjects 
(1,894 cases, 4,703 controls) were used in association testing. Supplementary Table 2 shows 
the distribution of subjects by participating study.
Imputation
Prediction of un-typed or partly genotyped SNPs was performed with BEAGLE 3.32 using 
the 1000 Genomes Project (phase 1, release 3) East Asians as reference panels for the 
Japanese data and Europeans and Africans for the African American data. Imputation was 
performed separately for the two ethnic groups with all cases and controls combined. 
Markers with MAFs < 0.005 in reference panels were excluded from imputation. For the 
African American data, 10,050,748 markers with imputation accuracy R2 > 0.8 were kept 
for association analysis; for Japanese data, 4,266,108 markers with imputation R2 > 0.95 
were retained. Altogether, 4,276,079 autosomal genotyped or imputed markers were 
available in both populations for meta-analysis.
Analysis of the Japanese and African American GWAS
Principal components (PCs) were calculated as in EIGENSTRAT15 with our own R 
program, including unrelated HapMap CEU, YRI and JPT samples as population controls. 
Ethnicity outliers were identified on PC plots by visual inspection and subsequently 
removed. Pair-wise PC plots suggested that the first two PCs were most informative for 
global ancestry and the distribution of PCs was similar among all cases and controls in both 
Japanese and African Americans (Supplementary Figures 1&2). Logistic regression of 
colorectal cancer on allelic dosage with adjustment for age at blood draw, sex and the first 4 
PCs was performed to obtain odds ratio (OR) estimates and 95% confidence interval (CI) of 
per increase in allele count with PLINK, where age was grouped as <55 years, 5-year 
intervals from 55 to 80, and ≥80 years. The genomic control factor (λ) was estimated from 
the median of the χ2 statistics divided by 0.456.
Heterogeneity of genetic effects by site (colon vs. rectal cancer, mutually exclusive), stage 
(regional/distant vs. local/in situ) and age at diagnosis (≤55 vs. > 55 years) was tested in a 
case-only analysis. Effect modification by sex was assessed comparing the model with and 
without the cross-product term. These and additional stratified analyses by site, stage, age at 
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diagnosis and sex were adjusted for age at blood draw, sex (where appropriate), the first 4 
PCs and BMI.
Conditional analyses were performed to examine independence of association signals in the 
chromosome 10 region, conditioning on the SNP with the smallest P-value. Significance of 
the additional contribution by other SNPs was calculated based on a likelihood ratio test. 
These analyses were carried out using SAS 9.3.
Local ancestry estimation for African Americans
The percentage of African ancestry (0, 50% or 100%, i.e. half of the estimated number of 
African chromosomes) was inferred for each participant at the putative chromosome 10 
locus (± 250kb) with the LAMP program v2.4 16. To summarize local ancestry at a CRC 
risk region, for each individual we averaged across all local ancestry estimates that are 
within the region. The effect of local ancestry was evaluated by examining the relative 
change in ORs with and without adjustment for local ancestry in logistic regression.
CORECT study for replication
The CORECT study meta-analysis was conducted using germline DNA the Molecular 
Epidemiology of Colorectal Cancer study (MECC) (set 1: 484 cases and 498 controls; set 2: 
1,120 cases and 820 controls), CCFR (set 1: 1,977 cases and 999 controls; set 2: 1,660 cases 
and 1,393 controls), Kentucky case-control study (1,038 cases and 1,134 controls), 
Newfoundland case-control study (548 cases and 538 controls), American Cancer Society 
CPS II nested case-control study (ACS/CPSII, 539 cases and 469 controls) and the 
Melbourne nested case-control study (195 cases and 477 controls). All subjects were self-
reported whites. The majority of the studies were genotyped using the Affymetrix Axiom 
CORECT Set containing approximately 1.3 million SNPs and indels on two physical 
genotyping chips (Supplementary Table 3). Genotype data were screened based on filters 
such as call rates, concordance rates, sample relatedness, and ethnic outliers. IMPUTE2 17 
was used to impute missing genotypes based on the cosmopolitan panel of reference 
haplotypes from Phase I of the 1000 Genomes Project. Imputed genotypes were screened 
based on stringent imputation quality and accuracy filters (info ≥ 0.7, certainty ≥ 0.9, 
concordance ≥ 0.9 between directly measured and imputed genotypes after masking input 
genotypes for genotyped markers only). Associations between genetic variants and CRC risk 
were tested using a log-additive genetic model within each study, allowing for study-specific 
adjustment for age, sex, study center, genotyping batch, and 2-4 principal components. More 
details of each participating study can be found in Supplementary Methods.
GECCO study for replication
The GECCO GWAS consortium has been described before18-20. The consortium consisted 
of European-descent participants within the French Association Study Evaluating RISK for 
sporadic colorectal cancer (ASTERISK, 948 cases and 947 controls); CR2&3 (87 cases and 
125 controls); Darmkrebs: Chancen der Verhütung durch Screening (DACHS set 1: 1710 
cases and 1707 controls; DACHS set 2: 675 cases and 498 controls); Diet, Activity, and 
Lifestyle Study (DALS set 1: 706 cases and 710 controls; DALS set 2: 410 cases and 464 
controls); Health Professionals Follow-up Study (HPFS set 1: 227 cases and 230 controls; 
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HPFS set 2: 176 cases and 172 controls); MEC (328 cases and 346 controls); Nurses’ Health 
Study (NHS set 1: 394 cases and 774 controls; NHS set 2: 159 cases and 181 controls); 
Ontario Familial Colorectal Cancer Registry (OFCCR, 650 cases and 522 controls); 
Physician's Health Study (PHS, 382 cases and 389 controls); Postmenopausal Hormone 
study (PMH, 280 cases and 122 controls); Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial (PLCO set 1: 533 cases and 1976 controls; PLCO set 2: 486 cases and 415 
controls); VITamins And Lifestyle (VITAL, 285 cases and 288 controls); and the Women's 
Health Initiative (WHI set 1: 470 cases and 1,529 controls; WHI set 2: 1,006 cases and 
1,010 controls). All individual studies were genotyped on Illumina arrays on 240k to 730k 
markers and went through rigorous QC. The genotype data were imputed to increase the 
density of genetic variants. The haplotypes from the 1000 Genomes Project Phase I were 
used as the reference panel. Logistic regression of colorectal cancer on SNP dosage effect on 
CRC risk was performed with adjustment for age, sex (when appropriate), center (when 
appropriate), smoking status (PHS only), batch effects (ASTERISK only), and the first three 
PCs from EIGENSTRAT 14 to account for population substructure within each individual 
studies. Additional details on sample collection, genotyping, QC and statistical methods are 
provided in Supplementary Methods.
All samples were collected with informed consent and all procedures were approved by the 
Human Research Institutional Review Boards (IRB) at relevant institutions. Specifically, 
The study protocols of the Japanese and African Americans GWAS were approved by the 
University of Hawaii Human Studies Program and University of Southern California IRB, 
the IRB in the National Cancer Center, Japan, the Ethics Committee of Kyushu University 
Faculty of Medical Sciences, the University of North Carolina IRB, Vanderbilt University 
IRB, the Fred Hutchinson Cancer Research Center IRB and the MD Anderson Cancer 
Center IRB. The GECCO portion of this work was approved by the Fred Hutchinson Cancer 
Research Center IRB. The University of Southern California Health Sciences IRB approved 
all elements of the CORECT study.
Meta-analysis
A fixed-effect model with inverse variance weighting implemented in METAL 21 was used 
to combine results from the Japanese and the African American studies and for further 
combining with replication studies. Heterogeneity measure I2 was calculated and Cochran's 
Q statistic to test for heterogeneity was calculated22. For the 12 top hits in the VTI1A region 
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regional P-value plots for the new colorectal cancer susceptibility locus at 10q25
Results in the Japanese (a) (n = 6,424), African Americans (b) (n = 6,595) and in the 
combined data (Japanese and African Americans) (c) are displayed. The SNP with the 
smallest P-value from meta-analysis in the combined data (n = 13,019), rs12241008, is 
shown as a purple diamond. r2 is in relation to this SNP from the 1000 Genomes Project in 
East Asians (a,c) or in Africans (b). The plot was generated using LocusZoom12.
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